Patents by Inventor Keijiro Samejima

Keijiro Samejima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic polyamines
    Patent number: 5880161
    Abstract: Therapeutic polyamines useful as a cancer chemotherapeutic agents, including molecules having a formula R.sub.1 --NH--(CH.sub.2).sub.x --NH-- (CH.sub.2).sub.x --NH-- (CH.sub.2).sub.y --NH--(CH.sub.2).sub.z --NH--R, wherein R.sub.1 and R.sub.2 are hydrocarbon chains having 1 to 5 carbons and w, x, y and z are integer of 1 to 10, are disclosed. One such molecule is N.sup.1, N.sup.19 -bis(ethylamino)-5,10,15-triazanonadecane, which is longer than spermine. This preferred compound may be used alone or in combination with other therapeutic agents, such as 1,3-bis(2-chloroethyl)-1-nitrosourea or cis-Pt.
    Type: Grant
    Filed: July 29, 1996
    Date of Patent: March 9, 1999
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Hirak Subhra Basu, Burt Feuerstein, Keijiro Samejima, Laurence Marton
  • Therapeutic polyamines
    Patent number: 5541230
    Abstract: Therapeutic polyamines useful as a cancer chemotherapeutic agents, including molecules having a formula R.sub.1 --NH--(CH.sub.2).sub.x --NH --(CH.sub.2).sub.x --NH--(CH.sub.2).sub.y --NH--(CH.sub.2).sub.z --NH--R, wherein R.sub.1 and R.sub.2 are hydrocarbon chains having 1 to 5 carbons and w, x, y and z are integers of 1 to 10, are disclosed. One such molecule is N.sup.1, N.sup.19 -bis(ethylamino)-5,10,15-triazanonadecane, which is longer than spermine. This preferred compound may be used alone or in combination with other therapeutic agents, such as 1,3-bis(2-chloroethyl)-1-nitrosourea or cis-Pt.
    Type: Grant
    Filed: November 5, 1993
    Date of Patent: July 30, 1996
    Inventors: Hirak S. Basu, Burt Feuerstein, Laurence Marton, Keijiro Samejima